Test–retest repeatability of myocardial oxidative metabolism and efficiency using standalone dynamic 11C-acetate PET and multimodality approaches in healthy controls
Myocardial efficiency measured by 11C-acetate positron emission tomography (PET) has successfully been used in clinical research to quantify mechanoenergetic coupling. The objective of this study was to establish the repeatability of myocardial external efficiency (MEE) and work metabolic index (WMI) by non-invasive concepts.
Methods and Results
Ten healthy volunteers (63 ± 4 years) were examined twice, one week apart, using 11C-acetate PET, cardiovascular magnetic resonance (CMR), and echocardiography. Myocardial oxygen consumption from PET was combined with stroke work data from CMR, echocardiography, or PET to obtain MEE and WMI for each modality. Repeatability was estimated as the coefficient of variation (CV) between test and retest. MEECMR, MEEEcho, and MEEPET values were 21.9 ± 2.7%, 16.4 ± 3.7%, and 23.8 ± 4.9%, respectively, P < .001. WMICMR, WMIEcho, and WMIPET values were 4.42 ± 0.90, 4.07 ± 0.63, and 4.58 ± 1.13 mmHg × mL/m2 × 106, respectively, P = .45. Repeatability for MEECMR was superior compared with MEEEcho but did not differ significantly compared with MEEPET (6.3% vs 12.9% and 9.4%, P = .04 and .25). CV values for WMICMR, WMIEcho, and WMIPET were 10.0%, 14.8%, and 12.0%, respectively, (P = .53).
Non-invasive measurements of MEE using 11C-acetate PET are highly repeatable. A PET-only approach did not differ significantly from CMR/PET and might facilitate further clinical research due to lower costs and broader applicability.
KeywordsPET MRI Echo Metabolic
Cardiovascular magnetic resonance
Forward stroke volume
Geometrical stroke volume
Mean arterial blood pressure
Myocardial external efficiency
Myocardial oxygen consumption
This study received financial assistance from the Lundbeck Foundation, Arvid Nilssons Foundation, Karen Elise Jensens Foundation, and Snedkermester Sophus Jacobsen & Hustru Astrid Jacobsens Foundation. Henrik Wiggers is principal investigator in studies involving the following pharmaceutical companies: Novo Nordisk, MSD, Bayer, Daiichi-Sankyo, Novartis, Sanofi-Aventis, and Pfizer. For Nils Henrik Hansson, Johannes Hendrik Harms, Lars Poulsen Tolbod, Won Yong Kim, Roni Nielsen, Jorgen Frokiaer, Kirsten Bouchelouche, Steen Hvitfeldt Poulsen, Erik Thorlund Parner, and Jens Sorensen there are no disclosures.
- 3.Lindner O, Sorensen J, Vogt J, Fricke E, Baller D, Horstkotte D, et al. Cardiac efficiency and oxygen consumption measured with 11C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med. 2006;47:378-83.Google Scholar
- 4.Beanlands RS, Nahmias C, Gordon E, Coates G, de Kemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102:2070-5.CrossRefGoogle Scholar
- 6.Guclu A, Knaapen P, Harms HJ, Vonk AB, Stooker W, Groepenhoff H, et al. Myocardial efficiency is an important determinant of functional improvement after aortic valve replacement in aortic valve stenosis patients: A combined PET and CMR study. Eur Heart J Cardiovasc Imaging. 2015;16:882-9.CrossRefGoogle Scholar
- 7.Nielsen R, Norrelund H, Kampmann U, Kim WY, Ringgaard S, Schar M, et al. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. Circ Heart Fail. 2013;6:845-52.CrossRefGoogle Scholar
- 11.Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med. 1998;39:272-80.Google Scholar
- 15.Harms HJ, Tolbod LP, Hansson NH, Kero T, Orndahl LH, Kim WY, et al. Automatic extraction of forward stroke volume using dynamic PET/CT: A dual-tracer and dual-scanner validation in patients with heart valve disease. EJNMMI Phys. 2015;2:25. Epub 2015 Oct 26.Google Scholar
- 19.Beanlands RS, Armstrong WF, Hicks RJ, Nicklas J, Moore C, Hutchins GD, et al. The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. J Nucl Cardiol. 1994;1:3-16.CrossRefGoogle Scholar
- 20.Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1993;22:1389-98.CrossRefGoogle Scholar
- 21.Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-20.CrossRefGoogle Scholar
- 23.Harms HJ, Hansson NH, Kero T, Baron T, Tolbod LP, Kim WY, et al. Automatic calculation of myocardial external efficiency using a single 11C-acetate PET scan. J Nucl Cardiol. https://doi.org/10.1007/s12350-018-1300-1.
- 27.Buck A, Wolpers HG, Hutchins GD, Savas V, Mangner TJ, Nguyen N, et al. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med. 1991;32:1950-7.Google Scholar